GLENMARK / FY26 summary

The year in one view.

Glenmark Pharmaceuticals · annual summary assembled from the available FY26 source records.

Research layer active

Revenue across quarters

38,346.9

₹ Cr where applicable

PAT across quarters

672

₹ Cr where applicable

Source quarters

11

₹ Cr where applicable

Revenue (₹ Cr)PositiveWatchNegative
11 actual records
Actual quarterly Revenue (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q1 FY24: 3,036 · Positive source sentiment · 2023-08-01Q1 FY24Q2 FY24: 3,207 · Watch source sentiment · 2023-10-31Q2 FY24Q3 FY24: 2,507 · Watch source sentiment · 2024-02-07Q3 FY24Q4 FY24: 3,063 · Watch source sentiment · 2024-05-28Q4 FY24Q1 FY25: 3,244.2 · Watch source sentiment · 2024-08-14Q1 FY25Q2 FY25: 3,433.8 · Watch source sentiment · 2024-10-30Q2 FY25Q3 FY25: 3,387.6 · Positive source sentiment · 2025-02-07Q3 FY25Q4 FY25: 3,256 · Watch source sentiment · 2025-05-15Q4 FY25Q1 FY26: 3,264.4 · Watch source sentiment · 2025-08-01Q1 FY26Q2 FY26: 6,046.9 · Positive source sentiment · 2025-10-30Q2 FY26Q3 FY26: 3,901 · Positive source sentiment · 2026-02-10Q3 FY266,046.92,507
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.